Assessment of the Efficacy of Photodynamic Therapy in Patients with Central Serous Chorioretinopathy

Document Type : Original Article(s)

Authors

1 Resident, Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associated Professor, Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

5 Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i830.1106

Abstract

Background: Photodynamic therapy (PDT) is known as an effective method in central serous chorioretinopathy (CSCR) in recent years. The aim of this study was to determine the efficacy of PDT in patients with CSCR.
Methods: This study was a prospective cohort study in patients with diagnosis of CSCR at the referral eye center. All necessary eye examinations and imaging for patients were done to diagnose the disease. The best corrected visual acuity (BCVA), contrast sensitivity at 3 and 6, 12 and 18 cycles per degree with CSV 1000 chart, color vision with Ishihara plates, central macular thickness (CMT) and central macular volume (CMV) was evaluated before and one month after PDT.
Findings: Fifty-six eyes of 56 patients with a female to male ratio of 2.5:1 and mean age of 9.41 ± 3.7 were evaluated. Significant improvement in BCVA, CMT and CMV was observed. The changes in contrast sensitivity and color vision one month after the intervention were not statistically significant (P> 0.05).
Conclusion: The most important results in the present study indicated that PDT has a significant improvement in patients' BCVA, CMT and CMV one month after PDT.

Keywords

Main Subjects

References

  1. Brodie FL, Charlson ES, Aleman TS, Salvo RT, Gewaily DY, Lau MK, et al. Obstructive sleep apnea and central serous chorioretinopathy. Retina 2015; 35(2): 238-43.
  2. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta ophthalmol 2008; 86(2): 126-45.
  3. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008; 115(1): 169-73.
  4. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103(12): 2070-80.
  5. Gäckle HC, Lang GE, Freissler KA, Lang GK. [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects] [in German]. Ophthalmologe 1998; 95(8): 529-33.
  6. Breukink MB, Dingemans AJ, den Hollander AI, Keunen JE, MacLaren RE, Fauser S, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol 2016; 11: 39-46.
  7. Bujarborua D. Long‐term follow‐up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 2001; 79(4): 417-21.
  8. Loo RH, Scott IU, FLYNN Jr HW, Gass JDM, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002; 22(1): 19-24.
  9. Ooto S, Hangai M, Sakamoto A, Tsujikawa A, Yamashiro K, Ojima Y, et al. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology 2010; 117(9): 1800-9, 1809.e1-2.
  10. Shanmugam PM, Agarwal Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2004; 24(6): 988-9.
  11. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23(3): 288-98.
  12. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23(6): 752-63.
  13. Pryds A, Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthal 2012; 90(8): 738-43.
  14. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87(12): 1453-8.
  15. Ozkaya A, Alkin Z, Ozveren M, Yazici AT, Taskapili M. The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study. Eye (Lond) 2016; 30(7): 1005-10.
  16. Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 2011; 46(3): 160-3.
  17. Kang NH, Kim YT. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy. Eye (Lond) 2013; 27(3): 387-91.
  18. Chan W-M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87(12): 1453-8..
  19. Moreno-Morillo FJ, Fernandez-Vigo JI, Guemes-Villahoz N, Burgos-Blasco B, Lopez-Guajardo L, Donate-Lopez J. Update on the management of chronic central serous chorioretinopathy. Arch Soc Esp Oftalmol (Engl Ed) 2021; 96(5): 251-64.
  20. Hanumunthadu D, Tan ACS, Singh SR, Sahu NK, Chhablani J. Management of chronic central serous chorioretinopathy. Indian J Ophthalmol 2018; 66(12): 1704-14.
  21. Chan W-M, Lai TYY, Lai RYK, Liu DTL, Lam DSC. Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy: One-Year Results of a Randomized Controlled Trial. Ophthalmology 2008; 115(10): 1756-65.
  22. Hua L, Lin B, Hong J, Min HB, Han WL, Zhou TY, et al. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Eur Rev Med Pharmacol Sci 2018; 22(2): 278-84.
  23. Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study. PloS One 2017; 12(7): e0181479.
  24. Gulkas S, Sahin O. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol 2020; 30(5): 1053-60.
  25. Lourthai P, Bhurayanontachai P. Pattern of Contrast Sensitivity Changes in Acute Central Serous Chorioretinopathy. J Ophthalmol 2017; 2017: 9053932.

Cidad P, Gonzalez E, Asencio M, Garcia J. Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy. Korean J Ophthalmol 2015; 29(5): 331-5

Journal of Isfahan Medical School
Volume 43, Issue 830
2nd Week, November
November and December 2025
Pages 1106-1111

Files

History

  • Receive Date: 08 April 2025
  • Accept Date: 05 August 2025

Share

How to cite

Statistics